Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A

2(33.3%)

Early Phase 1

2(33.3%)

Phase 1

1(16.7%)

Phase 4

1(16.7%)

6Total

N/A(2)

Early Phase 1(2)

Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07362602Early Phase 1Not Yet Recruiting

Exploratory Study on in Vivo CAR-T Therapy Targeting CD20 for the Treatment of Hematological Malignancies

Role: lead

NCT05752123Not ApplicableTerminated

A Study to Evaluate the Safety and Efficacy of ET-01 Transplantation in Subjects with Transfusion Dependent Β-Thalassaemia.

Role: collaborator

NCT04009525Phase 4Completed

Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major: A Multicenter, Prospective Clinical Study

Role: collaborator

NCT06107400Early Phase 1Recruiting

Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease

Role: lead

NCT06298630Not Yet Recruiting

Long-term Follow-up Study of BRL-101 for TDT

Role: collaborator

NCT06314529Recruiting

Long-term Follow-up Study of BHC001 for TDT

Role: collaborator

NCT04211480Not ApplicableCompleted

Safety and Efficacy Evaluation of γ-globin Reactivated Autologous Hematopoietic Stem Cells

Role: collaborator

NCT04205435Phase 1Terminated

β-globin Restored Autologous HSC in β-thalassemia Major Patients

Role: collaborator

All 8 trials loaded